## Reconciliation of conclusions with prior systematic reviews

	Current	<b>Lam, 2018</b> PMID <u>29293146</u>	<b>lankova, 2017</b> PMID <u>29271844</u>	<b>Huang, 2017</b> PMID <u>29168046</u>	Andriolo (Cochrane), 2017 PMID <u>28099689</u>	<b>Westwood, 2015</b> PMID <u>26569153</u>	<b>Prkno, 2013</b> PMID <u>24330744</u>
Efficacy: duration of antibiotic therapy	Reduces duration by 1.50 days in subgroup of trials that encourage stopping antibiotics before 5 days  No reduction when compared to protocolized care that uses CRP.	Reduces duration by 1.26 days (for trials using an antibiotic cessation strategy)	duration by 1.49 days. Search	by 1.66 days in subgroup of trials that only	Reduces duration by 1.28 days	Reduces duration by 3.19 days	Reduction. Hazard ratio 1.27
Heterogeneity	49% (after meta-regression)	84%	81%	71%	86%	95%	0%
Efficacy: mortality	Reduction. Risk ratio 0.85 (95% CI: 0.74 to 0.97)  No reduction when compared to protocolized care that uses CRP.	Reduction.  Risk Ratio 0.87 (95% CI, 0.77-0.98) (for trials using an antibiotic cessation strategy)		Reduction. Risk ratio 0.87 (95% CI 0.76–0.98)	No reduction. Risk ratio 0.92 (95% CI: 0.81 to 1.05)	No reduction. Risk ratio 0.98 (95% CI: 0.76 to 1.27)	No reduction. Risk ratio 1.02 (95% CI: 0.85 to 1.23)
Heterogeneity:	16% (in subgroup of trials that encouraging stopping antibiotics before 5 days)	0%	80%	0%	11%	0%	0%